title: Are current development programs realising the full potential of new agents?
authors.affiliation: Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, N-5021, Bergen, Norway. per.lonning@helse-bergen.no
authors.forename: Per Eystein
authors.initials: PE
authors.lastname: Lønning
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D019008:Drug Resistance, Neoplasm; D005260:Female; D015870:Gene Expression; D006801:Humans; D019394:Ki-67 Antigen / Q000235:genetics; D058990:Molecular Targeted Therapy; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D013678:Technology, Pharmaceutical
chemical_list: D000970:Antineoplastic Agents; D019394:Ki-67 Antigen; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases